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Introduction
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a major neglected parasitic disease endemic in South and Central America with an increasing number of cases reported in countries such as USA, Spain and Japan. 1, 2 Research into new therapies to treat Chagas disease must overcome a number of difficulties arising from the complex nature of the parasite's life cycle 3 and its extensive impact on the body. 4 Following infection with T. cruzi parasites, bloodform trypomastigotes enter cells and rapidly proliferate in amastigote form, causing acute illness with mild symptoms lasting for a few weeks. Treatment is effective at this point in 60-85% of cases, 5 but acute infection can also cause mortality in a small number of patients. 6 Parasites remain in the body as the disease progresses to an asymptomatic phase during which time patients may not be aware they are carriers of the parasite and may never develop the chronic form of the disease. Chronic Chagas disease can take as long as 15-20 years to present, during which time the amastigote form of T. cruzi has caused considerable damage to the heart and/or gastrointestinal tract via infiltration of soft tissues and stimulation of immune responses. 7 A recent epidemiological study of mortality related to Chagas disease in Brazil between 1999-2007 reported 97% of diagnosed Chagas related deaths were due to the chronic form of the disease. 6 T. cruzi is genetically highly diverse and is divided into six discrete typing units (DTUs) 8 which have the potential to vary in susceptibility to drug treatment. The current standard of care, benznidazole, is given at a high dose for 30-60 days, has undesirable side effects leading to poor patient compliance and has a limited and controversial impact against chronic Chagas disease. 5 The protracted nature of the illness, extent of parasite distribution into the body, monitoring of disease progression and determination of cure add complexity to clinical evaluation of existing and promising new treatments. 1, 5 CYP51 is a well-validated drug target for the inhibition of T. cruzi and a major drug target in the cytochrome P450 family. 9 The enzyme is an important part of sterol biosynthesis in eukaryotes, with inhibition causing a breakdown in membrane structural integrity, fluidity and permeability leading to deleterious down-stream effects. 10 Pioneering work by Urbina et al. brought antifungal CYP51 inhibitors to the forefront of T.
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cruzi drug discovery establishing the cross-reactivity of leading azole antifungal sterol biosynthesis inhibitors against T. cruzi in vitro and in vivo. [11] [12] [13] [14] More active second generation antifungals posaconazole and a ravuconazole pro-drug are the first compounds to enter clinical trials for the treatment of Chagas disease in more than 40 years. Other compounds targeting T. cruzi CYP51 include the tipifarnib series, [15] [16] [17] [18] dialkyl imidazoles, 19 LP10, 20 and indomethacin amides, 21 with current hit generation efforts potentially fueling further research. 22 The recently reported crystal structure of T. cruzi CYP51 with bound posaconazole and fluconazole is an important step forward in the ongoing story of this target opening up the opportunity for structure based drug design to address potential issues of drug resistance. 23, 24 We recently identified fenarimol (1), a fungicide used in agriculture since the mid-1970s, as having moderate in vitro activity against T. cruzi (IC50 350nM) following a targeted hit generation campaign 25 utilizing a phenotypic whole organism in vitro screen. 26 Fenarimol inhibits fungal CYP51 and is classified within the pyrimidine sub-class of fungal CYP51 inhibitors.
27
The ability of 1 to kill T. cruzi could occur by a similar mechanism and the outcome of mechanistic studies will be reported in due course. Structure-activity relationship (SAR) studies focused on improving potency and establishing in vivo efficacy arrived at optimised triaryl analogue 2, which was orally active in a stringent in vivo mouse model of acute T. cruzi infection. In a general effort to expand the chemical diversity of the fenarimol series and assess the subsequent impact of a scaffold hop on activity, selectivity over CYP3A4, solubility, oral exposure and ultimately in vivo efficacy, one aromatic ring of the triaryl pharmacophore of 1 and 2 was replaced with piperazine to give a new 1-(diarylmethyl)piperazinyl scaffold (3) which could be further derivatised on the piperazine N-4 atom ( Figure 1 ).
<Insert Fig. 1 here> 
Materials and Methods

Chemistry
The retro synthesis of scaffold 3 is illustrated in scheme 1. Benzophenones (8) were selected as convenient precursors due to their ease of synthesis from classical Friedel-Craft reactions, palladium catalysed acylations or addition of aryl organometallic reagents to Weinreb amide derivatives of carboxylic acids. 25 Straightforward reduction with sodium borohydride gave diarylmethanols (6) which were also prepared directly in gram quantities by addition of aryl Grignard or aryllithium species to aromatic aldehydes at low temperature. As both aromatic groups could be introduced as either the organometallic or aldehyde entity, the choice of reacting partners was determined by availability of reagents and reactivity of pendent substituents. Conversion of 6 to the corresponding chloro derivative 7 on reaction with thionyl chloride was followed by substitution with t-butyl piperazine-1-carboxylate to give BOC-protected scaffold-4. Simple acid mediated deprotection gave 5 in overall good yields. 
Biological evaluation
The new [phenyl(pyridin-3-yl)methyl]piperazinyl derivatives 13-66 were tested for their ability to inhibit T. cruzi in vitro in a whole parasite assay. Specifically, compounds were incubated with T. cruzi Tulahuen strain TcVI (a strain transfected with the -galactosidase gene). 26 Parasites in the extra cellular trypomastigote form were added to the plate wells seeded with L6 cells (rat skeletal myoblasts) and incubated for 48h to allow infection to establish before addition of test compounds and a further 4-day incubation period, exposing compounds to both the extracellular trypomastigote and intracellular amastigote forms of the parasite. An IC50 value was recorded corresponding to the concentration of compound required to inhibit 50% of parasite growth. Compound cytotoxicity was evaluated in L6-cells as a counter-screen. The compounds in this series were determined to be non-cytotoxic with selectivity ratios for T. cruzi:cytoxicity generally >100.
Compounds with good activity or those of structural interest were further evaluated for their propensity to undergo in vitro oxidative metabolism by hepatic microsomes and to inhibit CYP3A4, a key drug metabolising enzyme inhibited by most azole-derived CYP51 antifungals. Solubility in phosphate buffer at pH6.5 was also determined.
Suitable compounds with low to moderate predicted hepatic extraction ratios (Eh) were further evaluated in vivo by measurement of the oral exposure in non-infected Swiss outbred mice and subsequently, for in vivo efficacy in a mouse model of acute T. cruzi infection. 25 
Results and discussion
The exploration of the SAR was greatly facilitated by the tractable synthesis of the target compounds allowing each region of the pharmacophore to be investigated independently ( Figure  2 ).
<insert Figure 2 here>
Structure-activity relationship (SAR)
Exploration of the heterocycle and aromatic ring R 2 was guided by the results of previous SAR studies on the triaryl series, which had established 3-pyridyl and a handful of 4-substituted phenyl motifs as optimal for activity and in vitro oxidative metabolic stability (and thus oral exposure). 25 5-Pyrimidinyl analogues of several compounds were made in this study in order to confirm that SAR trends remained true in the new piperazine series. The bulk of the SAR exploration was thus focused on establishing the best R 1 group.
In general, across all variations of R 1 , the in vitro activity of the new piperazinyl compounds was very encouraging with activities in the low nM range. Tables 1-4 show selected analogues from the amide series (Table 1) , sulfonamide series (Table 2) , carbamate/carbonate series (Table 3 ) and aryl series ( Table 4 ). The compounds are ordered by in vitro activity starting with the most active analogue and a 2-fold difference in IC50 value was considered to reflect an actual difference in potency. Activity data for reference compounds posaconazole and benznidazole has been included in table 1. Posaconazole is very active in vitro, in contrast to the M activity level of benznidazole.
Considering each different R 1 in turn, for R 1 equal to amide (Table 1) bulky alkyl amido analogues 13-18 were more potent than benzamides 20 and 21. Thiazole 19 showed good activity. Pyrimidinyl analogues were less potent than the corresponding pyridyl compounds (e.g. 15 cf 23) and there was a slight preference for 2-F containing R 2 analogues (B and D) and a definite mismatch with R 2 = 4-benzonitrile (E). In contrast, the sulfonamide series (Table 2) showed a preference for aryl sulfonamides over alkyl analogues, and simple benzenesulfonamides 28 and 29 were very active. Additional Cl or iPr substituents did not enhance activity. Methyl sulfonamides 34, 35 and 37-42 provided an interesting sub-set of analogues with surprisingly active and equipotent pyridyl and pyrimidinyl lead compounds, and a clear preference for 2-F containing R 2 analogues B and D (34 cf 41 and 35 cf 38). Similar to the sulfonamide set, aromatic carbamates and carbonates (Table 3) were potent and more active than even bulky, lipophilic t-butyl analogues and pyridyl and pyrimidinyl analogues were equipotent. No activity advantage of carbamate-NH vs carbonate-O or for 2-F containing R 2 analogues was evident within the most potent aryl derivatives 43-48.
The R 1 equal to aryl (Table 4) series shared an activity level similar to the amide series. The set was very limited in scope, but quite electronically diverse analogues such as 57, 58 and 60 were essentially equiactive suggestive of a flat SAR and thus nonoptimal binding interactions. This can be understood by considering that the most active sulphonamide/carbonate/carbamate series have an aromatic ring extended into chemical space whereas the directly linked N-aryl analogues are shorter and linear and probably do not reach into the same binding pocket. 
c Tc = T. cruzi, values are the mean of at least two experiments; d L6 cells (rat myoblasts from skeletal muscle) for assessment of cytotoxicity; e 57 Het = 5-(3-methyl-1,2,4-oxadiazole).
Assessment of in vitro ADME and CYP3A4 inhibition profiles
Alongside the assessment of activity, compounds were screened in vitro for oxidative stability in human liver microsomes (to assess the likelihood of rapid hepatic clearance limiting systemic exposure after oral administration), solubility at pH 6.5 in phosphate buffer and selectivity for T. cruzi over CYP3A4 (a potentially limiting characteristic of the azole series and important for minimising potential drug-drug interactions for combination therapy). 28 Results for selected compounds are shown in Table 5 . kinetic solubility at pH 6.5 in phosphate buffer (g/mL) determined by nephelometry; c IC50 (M) for the inhibition of testosterone-β-hydroxylation by CYP3A4.
As is often the case, the most active compounds do not necessarily possess the best "drug-like" properties. From the amide series, methyl analogue 24 (T. cruzi IC50 240 nM) was very stable to oxidation by microsomes, had excellent solubility and only moderate activity at CYP3A4. Higher alkyl and more active analogues 15, 19, 14 and 17 (T. cruzi IC50 <40 nM) had acceptable profiles. The very active benzenesulfonyl analogues 28 and 29 (T. cruzi IC50 <10 nM) had disappointing profiles with Eh > 0.7 suggesting they would have poor exposure profiles in vivo. Carbamates/carbonates 48, 53, 50 and 52 had mixed profiles with no clear standout compounds, whilst compounds in the aryl series were highly metabolised and poorly soluble (data not shown). Pyrazinyl analogue 66 had minimal cross-reactivity with CYP3A4, but was 10-fold less active than leading pyridyl compounds and thus of no real interest. Not enough comparative data was collected to determine the influence of R 2 on in vitro ADME and physicochemical properties, but previous studies with the triaryl series showed that the rate of oxidative metabolism could be reduced by the inclusion of 4-trifluoromethylphenyl. 25 
Evaluation of oral exposure
The systemic exposures of 24 and 37 (citrate salt) were determined in non-infected male Swiss outbred mice after single oral doses of 20, 50 and 100 mg/kg administered by gavage. Both compounds exhibited rapid absorption after oral administration, with maximum concentrations attained approximately 15 min post-dose. No adverse reactions or compound-related side effects were observed following oral administration of either compound at the dose levels examined. The apparent half-lives of 37 (T 1/2 = 2.1-2.9 h) and 24 (T 1/2 =1.7 -2.7 h) were similar, however the AUC for 37 over the 7.5 h post-dose sampling period was higher than that for 24 at each comparable dose (37: AUC 0-7.5h (M.h) 7.2 at 20 mg/kg, 60.2 at 50 mg/kg and 43.7 at 100 mg/kg. 24: AUC 0-7.5h (M.h) 2.3 at 20 mg/kg, 6.2 at 50 mg/kg and 9.4 at 100 mg/kg) (See supplementary information for oral exposure profiles). Full-scan LC-MS data were collected for selected plasma samples to identify potential metabolites. Putative products of oxygenation and amide hydrolysis were detected for 24, and products of oxygenation and N-dealkylation were observed for 37. Potential metabolites having molecular weights consistent with the products of glucuronidation, sulphation or oxygenation followed by conjugation or ring opening were not detected.
Evaluation of in vivo efficacy
Compounds 24 and 37 were evaluated for in vivo efficacy in a mouse model of acute T. cruzi infection following doses of 20, 50 and 100 mg/kg. Female Swiss mice (n=5 per group) were infected with 25,000 blood form trypomastigotes of T. cruzi (Tulahuen strain/Tc VI). Compound dosing commenced on day 8 post infection (p.i.) and each mouse received the indicated dosage of compound in a single, once daily administration by oral gavage for 5 consecutive days. Blood parasitemia was evaluated on days 8, 9, 12 and 14 p.i. and expressed as "number of trypomastigotes/mL of blood". Compound efficacy was indicated by a decrease in parasitemia levels in comparison to vehicletreated mice on day 14 p.i.. Posaconazole (Noxafil®) treated mice (50 and 100 mg/kg) were used as a positive control alongside the vehicle only treated group.
<insert Figure 3 here>
Compared to vehicle-treated mice, 24 was unable to significantly reduce blood parasitemia at all doses tested (Fig.  3A) but was able to improve survival. All 24-treated mice survived to the end of the treatment period (day 14) whereas 60% of vehicle-treated mice did not survive past day 12 (Fig. 4A) . In contrast, 37-treated mice had significantly improved reduction in parasitemia when dosed at 100, 50 and 20 mg/kg (96%, 95% and 73%) compared to vehicle-treated on day 14, respectively) (Fig.  3B ). All 37-treated mice had improved survival outcomes relative to vehicle (4/5 mice at 20mg/kg; 5/5 at 50mg/kg and 4/5 at 100 mg/kg survived to the end of the experiment) (Fig. 4B) . This was comparable to the positive control, posaconazole, which reduced blood parasitemia to below detectable limits by day 14 p.i. in both 50 mg/kg and 100 mg/kg treated groups (Fig. 3C) , with 3/5 mice (50 mg/kg) and 4/5 mice (100 mg/kg) surviving to the end of the experiment (Fig. 4) .
<insert Figure 4 here>
Conclusions
Simple 1-[phenyl(pyridin-3-yl)methyl]piperazinyl analogues of fenarimol were investigated for their ability to inhibit T. cruzi in vitro in a whole parasite assay and further studied for in vivo efficacy in a mouse model of acute T. cruzi infection. A range of analogues bearing amide, sulfonamide, carbamate/carbonate and aryl substituents appended to [phenyl(pyridin-3-yl)methyl]piperazine scaffolds 3 exhibited low nM activities in vitro. Two compounds, 24 and 37, gave good plasma exposures in mice following oral administration and were tested for efficacy in vivo. Compound 37 was able to significantly reduce parasitemia in a mouse model of acute T. cruzi infection after once daily oral dosing at 20, 50 and 100 mg/kg for 5 days, consistent with a higher potency and overall superior plasma concentration profile compared to 24 which was not efficacious in vivo. The tractable synthesis of the target compounds, oral exposure profiles and demonstrated in vivo efficacy of 37 makes the 1-[phenyl(pyridin-3-yl)methyl]piperazinyl series an attractive target for further optimisation.
Experimental
General.
Reagents were purchased from commercial suppliers and used without further purification. Commercially available anhydrous solvents were used and stored under nitrogen, unless indicated otherwise. Reactions involving moisture sensitive reagents were conducted under an atmosphere of dry nitrogen in glassware dried with a heat-gun. Thin layer chromatography (TLC) using silica gel Merck 60 F254 plates and detection with UV light was used to monitor reactions. 1 H NMR spectra were recorded in CDCl 3 , CD 3 OD or DMSO-d6 solutions on a Varian 200, Brucker 300 or Varian 400MHz machine. Chemical shifts are reported in parts per million (δ) downfield of tetramethylsilane (TMS). GC-MS were acquired on an Agilent 5973 network machine. LC-MS were acquired on an Applied Biosystems / MDS Sciex API-2000 system. Flash chromatography was carried out with silica gel (0.04-0.06μm, 230-400 mesh), reverse phase silica gel (C18 35-70μm) or on a Flashmaster II system using cartridges prepared in-house. Microwave irradiations were conducted using a Biotage initiator. All compounds tested in the in vitro and in vivo biological screens were purified to >95% purity as determined by analysis of HPLC on an Agilent 1100 series machine, fitted with a C8 reverse phase Agilent zorbax eclipse DB-LB 4.6 x 150 mm 5μm column (flow rate 1.2mL/min; method 1: 20% acetonitrile in water, increasing to 60% acetonitrile over 10min; method 2: 50% acetonitrile in water increasing to 90% acetonitrile over 10min; method 3: 70% acetonitrile in water increasing to 95% acetonitrile over 10min); 1 H NMR spectra (accounting for noncompound peaks and residual solvent) and in some cases LC-MS or GC-MS. Fenarimol [60168-88-9] (1) was purchased from commercial sources and posaconazole was a gift from the CDCO.
Synthesis of compounds.
The preparation of [4-chlorophenyl(pyridin-3-yl)methyl]piperazine analogues 24, 29, 46, 47 and 62 is provided as a representative example of the synthetic methodology. The synthesis of compound 37 is also described. Methods and data for other reported compounds is available in the supplementary material.
Preparation of diarylmethanol intermediates (6) from benzophenones.
25
(4-Chlorophenyl)(pyridin-3-yl)methanol (9) . To a solution of 3-(4-chlorobenzoyl)pyridine (3g, 14mmol) in methanol (20mL) was slowly added sodium borohydride (0.72g, 20mmol). The mixture was stirred at room temperature under nitrogen for 48h, then concentrated, diluted with water (40mL) and extracted with chloroform (40mL). The organic layer was dried, filtered and the filtrate concentrated to afford 9 as a white solid (3g, 97%). (10) . A mixture of 9 (2.5g, 11mmol), thionyl chloride (5.2g, 44mmol) and toluene or dichloromethane (10mL) was stirred at room temperature for 2 h with a drying tube or heated under reflux overnight. On cooling, the mixture was concentrated and azeotroped with toluene (2x10mL) to afford 10 as a white solid (2.5g, 94%). 
Preparation of chloro diarylmethyl intermediates (7) from diarylmethanol intermediates (6).
3-[Chloro(4-chlorophenyl)methyl]pyridine
Preparation of diarylmethylpiperazine intermediates (4 and 5) from chloro diarylmethyl intermediates (7).
1-[(4-Chlorophenyl)(pyridin-3-yl)methyl]piperazine (12).
To a dry 100mL round bottomed flask fitted with a condenser and a stirrer bar was added 10 (5g, 21mmol). This was dissolved in anhydrous acetonitrile (40mL) and t-butyl piperazine-1-carboxylate (5.9g, 31.5mmol) was added followed by triethylamine (anhydrous, 5.9mL, 42mmol) and a catalytic amount of potassium iodide (dried by heat gun under vacuum). The reaction was heated at 80°C for 48 h. The reaction mixture was cooled, concentrated and the residue partitioned between dichloromethane (100mL) and a saturated aqueous sodium carbonate solution (100mL). The aqueous phase was re-extracted with dichloromethane (2x50mL), the organic phases combined, dried (sodium sulfate), filtered and concentrated to give a crude orange oil. Purification by Flashmaster II chromatography (eluent ethylacetate in dichloromethane 0-30%) gave BOC-intermediate 11 as a semi-pure solid (16.1g, 80%). 43 (s, 9H) . 11 (3.4g, 8.8mmol ) was dissolved in dichloromethane (40mL) and methanol (10 drops) was added. The mixture was cooled to 0°C and trifluoroacetic acid (6.5mL, 87.7mmol) was added drop wise. The mixture was stirred for 1 h at 0 o C, allowed to come to room temperature overnight, concentrated and azeotroped with dichloromethane to give 12 (3.7g) as the crude trifluoroacetic acid salt which was used without further purification. 
Preparation of diarylmethylpiperazine analogue libraries (3) from diarylmethylpiperazine intermediates (5). Method A.
Amides from acid chlorides. Chlorophenyl)(pyridin-3-yl)methyl]piperazin-1-yl}ethan-1-one (24). 12 (3.7g) was dissolved in anhydrous dichloromethane (30mL) and the solution cooled to 0°C. Triethylamine (5mL, 36mmol) was added drop wise with stirring. A further 5mL of triethylamine was added, followed by drop wise addition of acetyl chloride (1.0mL, 14.4mmol) and the mixture allowed to stir for 45 min, poured onto aqueous sodium carbonate solution (20mL) and extracted with chloroform (3x40mL). The organic phases were combined, dried (sodium sulfate), filtered and concentrated to give a dark orange oil which was purified by Flashmaster II chromatography (eluent chloroform in methanol) to give 24 (485mg, 17%) as a hygroscopic colourless solid. Sulfonamides from sulfonyl chlorides.
1-{4-[(4-
1-(Benzenesulfonyl)-4-[(4-chlorophenyl)(pyridin-3-yl)methyl]piperazine (29)
. 12 (250mg, 0.24mmol) was dissolved in dichloromethane (2.5mL) under an atmosphere of nitrogen and benzenesulfonyl chloride (0.46mL, 2eq) was added and the mixture cooled to 0°C. Triethylamine (0.6mL) was added and the mixture stirred for 2 hours then allowed to warm to room temperature, poured onto a saturated aqueous sodium carbonate solution (20mL) and extracted with dichloromethane (3x15mL). The organic phases were combined, dried (magnesium sulfate), filtered, concentrated and purified by Flashmaster II chromatography (eluent ethylacetate in dichloromethane) to give 29 as an off-white powder (86mg, 83%). Carbonates from chloroformates. Phenyl 4-[(4-chlorophenyl)(pyridin-3-yl)methyl]piperazine-1-carboxylate (46) A solution of 12 (0.3g) in dichloromethane (3mL) was cooled to 0°C and triethylamine (1.5mL) was added, followed by phenyl chloroformate (0.07mL, 0.58mmol). The mixture was allowed to warm to room temperature overnight, then 10mL of a saturated solution of ammonium chloride and 10mL of dichloromethane were added. The organic phase was separated and the aqueous phase re-extracted with dichloromethane (2x10mL). The organic phases were combined, dried (magnesium sulfate) filtered and concentrated. The crude material was purified by Flashmaster II chromatography (eluent ethyl acetate in hexanes) to give 46 (66mg, 56%) as an off-white solid. Triethylamine (2.0mL) was added, followed by phenyl isocyanate (52mg, 0.44mmol) and the mixture stirred for 30 min, poured into a saturated solution of sodium chloride (20mL) and extracted with dichloromethane (2x10mL). The organic phases were combined, dried (magnesium sulfate) filtered and concentrated. The crude material was purified by Flashmaster II chromatography (eluent ethyl acetate in hexanes) to give 47 (83mg, 70%) as a white solid. (11.3g, 47 .5mmol) in dichloromethane (140mL) was cooled to 0 o C and thionyl chloride (5.86mL, 80.8mmol) added. The reaction mixture was allowed to warm to room temperature over 2 h. The mixture was concentrated, re-extracted into dichloromethane and washed with an aqueous solution of sodium carbonate. The aqueous layer was treated with salt and re-extracted with dichloromethane (3x100mL). The organic layers were combined, dried (magnesium sulfate), filtered and concentrated to give 68 as a crude light brown oil (11.2g, 93%). 1 (11.2g, 43 .7mmol) was dissolved in anhydrous acetonitrile (100mL) and t-butyl piperazine-1-carboxylate (24.4g, 0.13mmol) was added followed by triethylamine (anhydrous, 12.2mL, 87.4mmol) and a catalytic amount of potassium iodide (dried by heat gun under vacuum). The reaction was heated at 80°C for 48 h (an additional 12mL triethylamine and 5g of t-butyl piperazine-1-carboxylate were added after 24h). The reaction mixture was cooled, concentrated and the residue partitioned between dichloromethane (100mL) and a saturated solution of sodium carbonate (100mL). The aqueous phase was re-extracted with dichloromethane (3x100mL), the organic phases combined, dried (sodium sulfate), filtered and concentrated to give a crude offwhite solid (16.3g, 92%). The crude material (4g, 9.85mmol) was dissolved in dichloromethane (40mL) and methanol (1mL) was added. The mixture was cooled to 0°C and trifluoroacetic acid (10mL, 135mmol) was added drop wise. The mixture was stirred for 4 days, concentrated and azeotroped with dichloromethane to give 69 (8.5g) as the crude trifluoroacetic acid salt as an orange oil which was used without further purification. 1 Chloro-2-fluorophenyl)(pyridin-3-yl) methyl]-4-methanesulfonylpiperazine (37). 69 (5g, 5.8mmol) was dissolved in a solution of dichloromethane (40mL) containing triethylamine (5mL) at 0 o C. Methanesulfonyl chloride (0.9mL, 11.6mmol) was added drop wise and the mixture stirred for 2 h then allowed to warm to room temperature, poured onto a saturated solution of ammonium chloride (20mL) and extracted with dichloromethane (3x30mL). The organic phases were combined, dried (magnesium sulfate), filtered, concentrated and purified by preparative HPLC (eluent 30% acetonitile in water) to give 37 as an off-white solid (690mg, 31% 
Biological assays.
General methods for the in vitro T. cruzi assay for determination of IC50, in vitro assay for determination of cytotoxicity, solubility, microsomal stability, cytochrome P450 3A4/5 and in vivo efficacy model of acute T. cruzi infection in mice as previously described. Table 1  Table 2  Table 3 Table 4 
